Reversible corneal edema associated with amantadine use: An unrecognized problem

Movement Disorders

Volumn 23, Issue 14, 2008, Pages 2096-2097

  Dubow, Jordan S ^a   Rezak, Michael ^a   Berman, Andrew A ^b  

^a Movement Disorders Center   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; PRAMIPEXOLE; SELEGILINE;

AGED; ARTICLE; BLURRED VISION; BRADYKINESIA; CASE REPORT; CLINICAL EXAMINATION; CORNEA EDEMA; DISEASE EXACERBATION; DRUG DOSAGE FORM COMPARISON; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EVENING DOSAGE; FEMALE; FOLLOW UP; HUMAN; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NEUROOPHTHALMOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TREMOR; VISUAL ACUITY;

AGED; AMANTADINE; ANTIPARKINSON AGENTS; CORNEAL EDEMA; FEMALE; HUMANS; MOVEMENT DISORDERS;

EID: 57049105151     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22136     Document Type: Article

References (5)

1. Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis 2006;194:S119-S126.
2. Fahn S, Isgreen WP. Long-term evaluation of amantadine and levodopa combination in parkinsonism by dobule-blind crossover analysis. Neurology 1975;25:695-700.
3. Metman LV, Del Potto P, Van Den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's Disease. Neurology 1998;50:1323-1326.
4. Hughes B, Feiz V, Flynn SB, et al. Reversible amantadine-induced corneal edema in an adolescent. Cornea 2004;23:823-824.
5. French DD, Margo CE. Postmarketing surveillance of corneal edema, Fuchs dystrophy, and amantadine use in Veterans Health Administration. Cornea 2007;26:1087-1089.